📢 #ESMO26 concomitant paper - Capivasertib plus abiraterone in PTEN-deficient de novo metastatic hormone-sensitive prostate cancer: updated survival analysis from CAPItello-281.

Annals of Oncology· @Annals_Oncology · X·2026-10-23 19:55· 2 days agoScore70

Body

📢 #ESMO26 concomitant paper - Capivasertib plus abiraterone in PTEN-deficient de novo metastatic hormone-sensitive prostate cancer: updated survival analysis from CAPItello-281.
🔗https://shorturl.at/c6tvw
@Daniel_J_George

1588 views · 10 likes · 4 reposts · 0 replies

Conference abstracts

LBA56NCT04746300matched by Rapid oral: Genitourinary tumours, prostate, penile and testis

Capivasertib (capi) + abiraterone (abi) vs placebo (pbo) + abi in patients (pts) with PTEN-deficient metastatic hormone-sensitive prostate cancer (mHSPC): Updated overall survival (OS) from CAPItello-281

https://esmocongress.esmo.org

Source: Annals of Oncology · x.com